跳至主要内容

Case Report: Long-Term Survival in Patient with Cirrhosis of the Liver and Colon Cancer K-ras Wild-Type

Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=47167#.VGBRb2fHRK0

K-ras wild-type carcinoma is a tumour that is sensitive to treatment with anti-cancer and anti-EGFR drugs: the combination of Cetuximab and Panitumumab with chemotherapy (Cetuximab) or as a single therapy (Panitumumab). Case Report: The clinical case presented here refers to a 68-year-old patient who had been diagnosed with adenocarcinoma of the recto sigmoid with pelvic recurrence three years after surgery. The patient had a severe co-morbidity: correlated B-type liver cirrhosis. First-line chemotherapy was begun with Oxaliplatin plus Capecitabine (CAPOXI) following a relapse, and this continued for six months (six cycles), when the treatment was interrupted because of the disease’s progression and hematological and gastrointestinal toxicity. Following an assessment of the K-ras, diagnosed as wild type, the patient was excluded from second-line chemotherapy treatment because of decompensated cirrhosis and the persistence of thrombocytopenia and leukopenia. The patient was put forward for biological treatment with an anti-EGFR monoclonal antibody (Panitumumab). Panitumumab was administered at a dosage of 6 mg/kg every 2 weeks for 17 months; the treatment was well tolerated, despite the cirrhosis, and the main toxicity was the skin rash. Conclusion: In patients with severe comorbidities such as cirrhosis of the liver and K-ras wild-type carcinomas, therapy with a monoclonal antibody such as Panitumumab is a treatment that is well tolerated, with few serious toxic side-effects; it also offers advantages in terms of survival and clinical benefits.
Cite this paper
Barletta, E. , Cannella, L. , Tinessa, V. , Germano, D. and Daniele, B. (2014) Case Report: Long-Term Survival in Patient with Cirrhosis of the Liver and Colon Cancer K-ras Wild-Type. Case Reports in Clinical Medicine, 3, 373-377. doi: 10.4236/crcm.2014.36083. 
 

[1] Cassidy, J., Tabernero, J., Twelves, C., et al. (2004) XELOX (Capecitabine plus Oxaliplatin): Active First-Line Therapy for Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 22, 2084-2091.
http://dx.doi.org/10.1200/JCO.2004.11.069
[2] Oh, S.C., Sur, H.Y. and Sung, H.J. (2007) A Phase II Study of Biweekly Dose-Intensified Oral Capecitabine plus Irinotecan (bXELIRI) for Patients with Advanced or Metastatic Gastric Cancer. British Journal of Cancer, 96, 1514-1519.
http://dx.doi.org/10.1038/sj.bjc.6603752
[3] Wisinski, K.B., Mulcahy, M.F. and Benson, A.B. (2007) Panitumumab in Metastatic Colorectal Cancer. Clinical Advances in Hematology and Oncology, 5, 10-11.
[4] Allegra, C.J., Jessup, J.M. and Somerfield, M.R. (2009) American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. Journal of Clinical Oncology, 27, 2091-2096.
http://dx.doi.org/10.1200/JCO.2009.21.9170
[5] Di Fiore, F., Charbonnier, F. and Lefebure, B. (2008) Clinical Interest of KRAS Mutation Detection in Blood for Anti-EGFR Terapie in Metastatic Colorectal Cancer. British Journal of Cancer, 99, 551-552.
http://dx.doi.org/10.1038/sj.bjc.6604451
[6] Karapetis, C.S., Khambata-Ford, S. and Jonker, D.J. (2008) KRAS Mutations and Benefit for Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359, 1747-1765.
http://dx.doi.org/10.1056/NEJMoa0804385
[7] Siddiqui, A.D. and Piperdi, B. (2010) KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy. The Annals of Surgical Oncology, 17, 1168-1176.
[8] McNeil, C. (2008) KRAS Mutations Are Changing Practice in Advanced Colorectal Cancer. Journal of the National Cancer Institute, 100, 1667-1669.
http://dx.doi.org/10.1093/jnci/djn429
[9] Amado, R.G., Wolf, M. and Peeters, M. (2008) Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 26, 626-634.
http://dx.doi.org/10.1200/JCO.2007.14.7116
[10] Lievre, A., Bachet, J.B. and Le Corre, D. (2008) KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. Journal of Clinical Oncology, 26, 374-379.
http://dx.doi.org/10.1200/JCO.2007.12.5906
[11] Di Fiore, F., Charbonnier, F. and Lefebure, B. (2008) Clinical Interest of KRAS Mutation Detection in Blood for Anti-EGFR Terapie in Metastatic Colorectal Cancer. British Journal of Cancer, 99, 551-552.
http://dx.doi.org/10.1038/sj.bjc.6604451
[12] Seront, E., Marot, L. and Coche, E. (2010) Successful Long-Term Management of a Patient with Late-Stage Metastatic Colorectal Cancer Treated with Panitumumab. Cancer Treatment Reviews, 36, S11-S14.
http://dx.doi.org/10.1016/S0305-7372(10)70002-5
[13] Van Cutsem, E., Peeters, M. and Siena, S. (2007) Open-Label Phase III Trial of Panitumumab plus Best Supportive Care Compared with Best Supportive Care Alone in Patients with Chemotherapy-Refractary Metastatic Colorectal Cancer. Journal of Clinical Oncology, 25, 1658-1664.
http://dx.doi.org/10.1200/JCO.2006.08.1620
[14] Lacouture, M.E., Mitchell, E.P. and Piperdi, B. (2010) Skin Toxicity Evaluation Protocol with Panitumumab (STEEP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of Pre-Emptive Skin Treatment Regimen on Skin Toxicties and Quality of Life in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 28, 1351-1357.
http://dx.doi.org/10.1200/JCO.2008.21.7828
[15] Pinto, C., Barone, C.A., Girolomoni, G., et al. (2011) Mana-gemente of Skin Toxcity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. Oncologist, 16, 228-238.
http://dx.doi.org/10.1634/theoncologist.2010-0298
[16] Ishiyama, Y., Kotake, M. and Matsunaga, M. (2012) Two Cases of Metastatic Colorectal Cancer in Wild-Type KRAS Effectively Treated by Pani-tumumab. Gan To Kagaku Ryoho, 39, 1567-1570.
[17] Peeters, M., Price, T.J. and Cervantes, A. (2010) Randomized Phase III Study of Panitumumab with Fluorouracil, Leucovorin an Irinotecan (FOLFIRI) Compared with FOLFIRI Alone as Second-Line Treatment in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 28, 4706-4713.
http://dx.doi.org/10.1200/JCO.2009.27.6055
[18] Raymond, E., Boige, V. and Faivre, S. (2002) Do-sage Adjustment and Pharmacockinetic Profile of Irinotecan in Cancer Patients with Hepatic Dysfunction. Journal of Clinical Oncology, 20, 4303-4312.
http://dx.doi.org/10.1200/JCO.2002.03.123
[19] Duillard, J.Y., Peeters, M. and Siena, S. (2008) Phase III Study (PRIME) of Panitumumab with FOLFOX-4 Compared to FOLFOX4 Alone in Patients with Previously Untreated Metastatic Colorectal Cancer. Preliminary Safety Data. Journal of Clinical Oncology, 28, 153.
[20] Cunningham, D., Humblet, Y. and Siena, S. (2004) Cetuximab Monotherapy a Cetuximab plus Irinotecan in Irinotecan Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 351, 337-345.
http://dx.doi.org/10.1056/NEJMoa033025
[21] Lacouture, M.E. and Melosky, B.L. (2007) Cutaneous Reactions to Anticancer Agents Targeting the Epidermal Growth Factor Receptor: A Dermatology-Oncology Persepective. Skin Therapy Letters, 12, 1-5.       eww141110lx
标签：

评论

发表评论

此博客中的热门博文

Does Immigration Promote the Investment of the Monopolistic Firm?

In the present paper, we examine the effect of increasing uncertainty of immigrants’ growth on the optimal timing of investment of a firm that has a monopolistic power over the labor market. It is revealed that when the uncertainty of immigrants’ growth is more than a threshold level, increasing uncertainty of immigrants’ growth accelerates the optimal timing of firms’ investment and enhances the economic growth, even if the uncertainty of immigrants’ growth is formulated by the geometric Brownian motion, which is in sharp contrast to the standard result that an increase in the uncertainty postpones the optimal timing. With an increase in the immigrants over the past ten years, workforces in the host countries have been growing significantly to the extent that the immigrants represent 70% of the increase in the workforce in Europe, and 47% in the United States as OECD indicates. In the present paper, we attempted to investigate the effect of increased uncertainty caused by the growi...
发表评论
阅读全文

Education Policy Implementation: A Mechanism for Enhancing Primary Education Development in Zanzibar

Education is one of the fundamental rights of individuals; therefore, the government of a country needs to develop and strengthen educational policy and quality as well as to ensure that everyone has equal access to basic education. The improvement of access and quality of education in the world is becoming as an essential factor in development, whereas the basic education (primary school), is acknowledged as a foundation of the higher educational development for every country. To fulfill this goal, governments introduce several policies and procedures; however, it requires some reforms and participation from the politician, policymakers, and other stakeholders to re-examine educational policy so that it can lead to multiplication and betterment of the reforms. Educational reforms actually focus on accountability. A positive educational development and reform is very challenging and needs more effort and strategy on how to use and utilize the resources effectively as such it can achie...
发表评论
阅读全文